The value of adding a second antiepileptic drug in intractable epilepsy with complexpartial seizures was studied in a long-term prospective trial in 30 adult patients who failed to respond to the maximum use of carbamazepine, phenytoin, phenobarbital or primidone as the first drug. Based on the individual previous history of one-drug treatment, the most promising antiepileptic drug (carbamazepine, clobazam, clonazepam, phenobarbital, phenytoin, primidone, valproic acid) was added, if necessary until clinical toxicity occurred. A reduction of the seizure frequency by more than 75% was seen in only four patients (13%) exposed to a second drug in the event of failure of optimum one-drug treatment. The remaining majority of patients (87%) did not benefit from the second drug; in three patients the seizure frequency increased by more than 100%. The common practice of adding another drug in difficult-to-treat cases may need to be reconsidered until further evidence is presented that two drugs are more beneficial than one drug in the treatment of intractable epilepsy.
One-drug treatment for epilepsy has considerable effectiveness in previously untreated patients. ' However, one-drug treatment is less promising in chronically treated patients. This was demonstrated recently in a prospective study of phenytoin therapy in a group of 30 patients with frequent complexpartial seizures. In 22 patients (73%) adequate control of the seizures was not obtained despite optimum one-drug treatment with therapeutic drug monitoring. There remain several options for further treatment in patients in whom adequate one-drug treatment failed. An alternative drug may be chosen or a second drug may be added. Although two or more antiepileptic drugs are used in the majority of chronic patients, there is surprisingly little evidence to evaluate the advantage of using two antiepileptic drugs instead of one. ' Among the various reasons for giving a patient more than one antiepileptic drug, the apparent lack of response to the first drug, several types of seizures, traditional approaches, personal opinion, and the availability of drugs are most frequently given.
Furthermore, the patient or his relatives may exert pressure on the physician to add another drug in the face of uncontrolled seizures. Yet the most important factor seems to be the concept that adding another drug will improve the therapeutic efficacy of the drug treatment. Unfortunately multiple antiepileptic drug treatment is associated with a number of problems: chronic toxicity, drug interactions, failure to evaluate the individual antiepileptic drug, and possibly the exacerbation of seizures in some patients.' It may therefore be useful to consider what would be acceptable evidence that two-drug treatment is preferable to one-drug treatment. It is necessary to ensure that the first drug has been used to its maximum capacity-that is, the highest tolerable plasma concentration. Furthermore, therapeutic drug monitoring will have to be employed to detect changes in the plasma concentration of the first drug when the second drug is given. If the plasma concentration of the first drug increases through an interaction with the second drug, the observed clinical effect may also have been produced directly by an increased dose of the first drug. In order to evaluate one-drug versus two-drug treatment, it is necessary to undertake prospective studies in groups of patients who have failed to respond to the optimum use of the first drug as suggested by Reynolds and Shorvon.' Such a study has been performed in 30 patients with complex-partial seizures uncontrolled by one-drug treatment who received a second antiepileptic drug.
Patients and methods
Thirty adult patients with intractable complex-partial seizures were chosen who remained uncontrolled despite one-drug treatment with either phenytoin, carbamazepine, primidone or phenobarbital at the highest tolerable plasma concentrations. It is our policy to increase the dose of the drug if necessary until toxicity occurs. The clinical data of this group of chronic patients are given in table 1. The previous drug regimen of the individual patient. The policy was to select one of the standard drugs (phenytoin, carbamazepine, or primidone/phenobarbital) which had previously not been shown to be ineffective in a controlled fashion (that is with monitoring of plasma concentrations) in our Epilepsy Clinic or elsewhere. In four patients phenytoin was added, in 10 patients carbamazepine and in 11 patients primidone or phenobarbital were given as the second drug. In five patients none of these four drugs seemed promising; in these cases valproic acid or clobazam were added in two patients and clonazepam was introduced as secondary antiepileptic drug in one patient. In subsequent visits clinical parameters were monitored in a protocol identical to that during the previous one-drug treatment. The second drug was slowly increased in dose until seizure control or clinical toxicity was seen. The dose of the first drug was reduced individually until clinical toxicity disappeared before the second drug was introduced. Clinical toxicity of valproic acid was indicated by tremor, that of benzodiazepines by drowsiness, sedation or irritability.5 During the initial phase of the two-drug treatment it was necessary to reduce the dose of the first drug in two patients due to side effects. The highest steady state plasma concentration of the two antiepileptic drugs, the duration of treatment and the mean weekly seizure frequency were recorded. The average duration of the twodrug treatment was 41-8 + 37 weeks, with a range of 6-3-147-9 weeks (tables 2-4). The average duration of the total study with one-drug treatment and subsequent two-drug treatment was 81 0 + 48 (SD) weeks, with a range of 11-207 weeks.
The efficacy of two-drug treatment was evaluated by comparison of the average weekly seizure frequency with the previous one-drug treatment period. 
Discussion
The addition of a second drug for epilepsy uncontrolled by one-drug treatment is based on the widely accepted concept that the second drug increases the therapeutic efficacy of the drug treatment. This concept may be based on a pitfall in interpretation of the common clinical impression that seizure control may improve when a second drug is added. If the first drug was not given in sufficiently high dosage, the improved seizure control cannot be reliably attributed to the second drug as optimum use of the first drug alone may have achieved the same therapeutic result. The clinical experience shared by many physicians does therefore not provide conclusive evidence in favour of two-drug treatment. In fact, this study indicates that the desired therapeutic result is reached in only 13% of the patients exposed to a second drug in the event of failure of optimum one-drug treatment. The remaining great majority of patients did not benefit from the two-drug treatment and in three patients (10%) the epilepsy even increased in seizure frequency more than 100% despite the second drug treatment.
Before the pathogenetic mechanism for this surprising lack of efficacy of two-drug treatment is considered, it may be useful to review the literature for acceptable evidence how often a second drug was successful when optimum one-drug treatment failed. In a retrospective survey of 50 chronic patients on two antiepileptic drugs, the addition of a second drug was associated with a reduction of seizure frequency by 50% or more in only 36% of the patients, and when it did occur, it was usually associated with optimum blood levels of at least one of the drugs.6 In prospective trials of mostly pretreated chronic patients with complex-partial seizures the addition of a second drug7 either carbamazepine,89 primidone,9 ' or phenobarbital" did not result in complete seizure control when the first drug was given in sufficiently high dose. In one recent study, the number of seizures decreased by more 
